The Role of Complement in the Antiphospholipid Syndrome

2003 ◽  
pp. 133-148 ◽  
Author(s):  
J.E. Salmon ◽  
G. Girardi
Keyword(s):  
Antiphospholipid Syndrome

scholarly journals Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management

2021 ◽  
Vol 23 (2) ◽  
Author(s):  
Silvia Rosina ◽  
Cecilia Beatrice Chighizola ◽  
Angelo Ravelli ◽  
Rolando Cimaz
Keyword(s):  
Antiphospholipid Syndrome ◽  
Fluid Phase ◽  
Multiple Organ ◽  
Clinical Settings ◽  
Glycoprotein I ◽  
Long Term Follow Up ◽  
Pediatric Populations ◽  
Cellular Components

Abstract Purpose of Review Elucidating the pathogenic mechanisms mediated by antiphospholipid antibodies (aPL) might exert important clinical implications in pediatric antiphospholipid syndrome (APS). Recent Findings aPL are traditionally regarded as the main pathogenic players in APS, inducing thrombosis via the interaction with fluid-phase and cellular components of coagulation. Recent APS research has focused on the role of β2 glycoprotein I, which bridges innate immunity and coagulation. In pediatric populations, aPL should be screened in appropriate clinical settings, such as thrombosis, multiple-organ dysfunction, or concomitant systemic autoimmune diseases. Children positive for aPL tests often present non-thrombotic non-criteria manifestations or asymptomatic aPL positivity. In utero aPL exposure has been suggested to result in developmental disabilities, warranting long-term follow-up. Summary The knowledge of the multifaceted nature of pediatric APS should be implemented to reduce the risk of underdiagnosing/undertreating this condition. Hopefully, recent pathogenic insights will open new windows of opportunity in the management of pediatric APS.

Cardiac involvement in antiphospholipid syndrome: The diagnostic role of noninvasive cardiac imaging

2016 ◽  
Vol 45 (5) ◽  
pp. 611-616 ◽  
Author(s):  
Sophie I. Mavrogeni ◽  
Petros P. Sfikakis ◽  
George D. Kitas ◽  
Genovefa Kolovou ◽  
Maria G. Tektonidou
Keyword(s):  
Antiphospholipid Syndrome ◽  
Cardiac Imaging ◽  
Cardiac Involvement ◽  
Noninvasive Cardiac Imaging ◽  
Diagnostic Role

The Role of Antiphospholipid Syndrome in Critical Illness

2000 ◽  
pp. 419-425 ◽  
Author(s):  
F. M. K. Williams ◽  
G. R. V. Hughes ◽  
R. M. Leach
Keyword(s):  
Critical Illness ◽  
Antiphospholipid Syndrome

scholarly journals Pathogenic and Therapeutic Role of Vitamin D in Antiphospholipid Syndrome Patients

10.5772/65071 ◽  
2017 ◽  
Author(s):  
Svetlana Jelic ◽  
Dejan Nikolic ◽  
Dragomir Marisavljević ◽  
Ljudmila Stojanovich
Keyword(s):  
Vitamin D ◽  
Antiphospholipid Syndrome ◽  
Therapeutic Role

Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome

2018 ◽  
Vol 56 (6) ◽  
pp. 939-946 ◽  
Author(s):  
Shulan Zhang ◽  
Ziyan Wu ◽  
Wen Zhang ◽  
Jiuliang Zhao ◽  
Gary L. Norman ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Arterial Thrombosis ◽  
Diagnostic Performance ◽  
Positive Likelihood Ratio ◽  
Chinese Patients ◽  
Healthy Controls ◽  
Patients At Risk

AbstractBackground:Increasing evidence has highlighted the role of non-criteria antiphospholipid antibodies (aPLs) as important supplements to the current criteria aPLs for the diagnosis of antiphospholipid syndrome (APS). In this retrospective study, we evaluated the clinical relevance of antibodies to phosphatidylserine/prothrombin (aPS/PT) in Chinese patients with APS.Methods:A total of 441 subjects were tested, including 101 patients with primary APS (PAPS), 140 patients with secondary APS (SAPS), 161 disease controls (DCs) and 39 healthy controls (HCs). Serum IgG/IgM aPS/PT was determined by ELISA.Results:The levels of IgG/IgM aPS/PT were significantly increased in patients with APS compared with DCs and HCs. IgG and IgM aPS/PT were present in 29.7% and 54.5% of PAPS, and 42.1% and 53.6% of SAPS, respectively. For diagnosis of APS, IgG aCL exhibited the highest positive likelihood ratio (LR+) of 21.60, followed by LA (13.84), IgG aβ2GP1 (9.19) and IgG aPS/PT (8.49). aPS/PT was detected in 13.3% of seronegative PAPS patients and 31.3% of seronegative SAPS patients. LA exhibited the highest OR of 3.64 in identifying patients with thrombosis, followed by IgG aCL (OR, 2.63), IgG aPS/PT (OR, 2.55) and IgG aβ2GP1 (OR, 2.33). LA and IgG aCL were correlated with both arterial and venous thrombosis, whereas IgG aPS/PT and IgG aβ2GP1 correlated with venous or arterial thrombosis, respectively.Conclusions:Our findings suggest that the inclusion of IgG/IgM aPS/PT may enhance the diagnostic performance for APS, especially in those in whom APS is highly suspected, but conventional aPLs are repeatedly negative. In addition, IgG aPS/PT may contribute to identify patients at risk of thrombosis.

scholarly journals Is there a role for immunosuppression in antiphospholipid syndrome?

Hematology ◽  
2019 ◽  
Vol 2019 (1) ◽  
pp. 426-432 ◽  
Author(s):  
Ecem Sevim ◽  
Rohan Willis ◽  
Doruk Erkan
Keyword(s):  
Antiphospholipid Syndrome ◽  
Vascular Endothelial Cell ◽  
Autoimmune Disorder ◽  
Vascular Endothelial ◽  
Rheumatologic Disease ◽  
Pregnancy Morbidity ◽  
Mechanistic Target Of Rapamycin ◽  
Disease Modifying Agents ◽  
Cell Inhibition

Abstract Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombosis, pregnancy morbidity, or nonthrombotic manifestations in patients with persistently positive antiphospholipid antibodies (aPL). Conventional APS treatment focuses on antithrombotic strategies, which are usually ineffective for the microvascular and nonthrombotic manifestations of aPL. Using a case-based presentation, this review focuses on the role of immunosuppression in nonobstetric APS, including B-cell inhibition (rituximab, belimumab, and bortezomib), complement inhibition (eculizumab), mechanistic target of rapamycin inhibition (sirolimus), vascular endothelial cell modulation (defibrotide), statins, and traditional rheumatologic disease–modifying agents (hydroxychloroquine, mycophenolate mofetil, azathioprine, and cyclophosphamide).

Possible role of polyclonal Immunoglobulin G (IgG) of patients with different clinical manifestations of the antiphospholipid syndrome on activation of inflammation biomarkers

Placenta ◽  
2019 ◽  
Vol 83 ◽  
pp. e86-e87
Author(s):  
Carlos Mario Rodríguez Colorado ◽  
Manuela Velasquez Berrío ◽  
Diana Carolina Rúa Molina ◽  
Angela María Álvarez Gomez ◽  
Angela Patricia Cadavid Jaramillo
Keyword(s):  
Antiphospholipid Syndrome ◽  
Immunoglobulin G ◽  
Clinical Manifestations ◽  
Polyclonal Immunoglobulin

The role of infectious diseases in the catastrophic antiphospholipid syndrome

2015 ◽  
Vol 14 (11) ◽  
pp. 1066-1071 ◽  
Author(s):  
M. Garcia-Carrasco ◽  
C. Mendoza-Pinto ◽  
S. Macias-Diaz ◽  
F. Vazquez de Lara ◽  
I. Etchegaray-Morales ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Antiphospholipid Syndrome ◽  
Catastrophic Antiphospholipid Syndrome
Sign in / Sign up

Export Citation Format

Share Document